KLK4 and hereditary angioedema: Lanadelumab is a fully human monoclonal antibody inhibiting plasma kallikrein (pKal) approved for the prevention of HAE attacks in patients with HAE aged ≥12 years in multiple countries and regions, including the United States, the European Union, Canada, and China (13–17).